Diabetes Care.:减重手术对早发性肥胖有效

2020-03-13 国际糖尿病 idiabetes

越来越多的证据表明减重手术可以持续减轻体重、改善伴随疾病和延长生存期。早发性肥胖症患者和成年肥胖症患者接受减重手术是否同样获益呢?根据Diabetes Care发表的一项研究结果表明,20岁之前患肥胖

越来越多的证据表明减重手术可以持续减轻体重、改善伴随疾病和延长生存期。早发性肥胖症患者和成年肥胖症患者接受减重手术是否同样获益呢?根据Diabetes Care发表的一项研究结果表明,20岁之前患肥胖症且接受减重手术的成年人可能会获益更多。


研究概要


瑞典哥德堡大学Johanna C. Andersson-Assarsson博士团队评估了37岁至60岁之间接受减重手术的2007例患者及与其对照的未接受减重手术的2040例患者的体重变化及2型糖尿病、微血管和心血管疾病进展。受试者自述了20岁时的体重,研究人员根据这些数据将接受减重手术的患者分为早期肥胖组(BMI 30 kg/㎡;n=528;平均年龄44.9岁;女性68.6%),早期超重组(BMI 25-29.99 kg/㎡; n =744;平均年龄47岁; 女性69.5%)和早期正常体重组(BMI<25kg/㎡,n=725,平均年龄49岁,女性73.8%)。未接受减重手术者进行相同分组:早期肥胖组(n=439,平均年龄46.1岁,女性70.2%),早期超重组(n=721,平均年龄48.7岁,女性68.9%)和早期正常体重组(n = 869,平均年龄 50岁,女性73.2%)。

研究人员在术后6个月随访受试者,之后4年每年随访一次,之后6年每两年随访一次。每次随访时评估体重,同时使用瑞典死因登记和国家患者登记确诊2型糖尿病、微血管和心血管并发症。

主要结果


接受手术治疗的早期肥胖症患者与未接受手术者相比,术后10年内发生2型糖尿病的危险降低了87%(OR = 0.13; 95%CI:0.07~0.025),而早期超重者(OR=0.13 ;95%CI,0.08-0.22)和早期正常体重者(OR =0.15;95%CI:0.09-0.24)罹患此病的风险也都降低。

相反,接受手术治疗且患有2型糖尿病的早期肥胖症患者与未接受手术者相比,术后10年内更容易进入糖尿病缓解期(OR=5.58;95%CI:1.11-27.96),早期超重者(OR=4.9; 95%CI:1.69-14.17)和早期正常体重者(OR=4.51; 95%CI:1.58-12.86)也是如此。

对于接受手术的早期肥胖患者,无论是否存在2型糖尿病(HR=0.4;95%CI:0.22-0.73)与未接受手术的患者相比,微血管并发症的风险也显著降低(HR=0.39;95%CI:0.23-0.66)。

Andersson-Assarsson评述到:“我们本来预期早发性肥胖组接受减重手术后体重减轻少、预防肥胖症合并症效果差,但并非如此。早发性肥胖组较成年肥胖者体重减轻甚至稍微多,糖尿病缓解,微血管并发症或糖尿病、心血管疾病和癌症的发生率没有差异。”

原始出处:
Kristensson FM, et al. Effects of Bariatric Surgery in Early- and Adult-Onset Obesity in the Prospective Controlled Swedish Obese Subjects Study. Diabetes Care. 2020;doi:10.2337/dc19-1909.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1761335, encodeId=f9331e6133553, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Sat Mar 14 08:58:33 CST 2020, time=2020-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1664097, encodeId=bf77166409e04, content=<a href='/topic/show?id=a20c59283e5' target=_blank style='color:#2F92EE;'>#早发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59283, encryptionId=a20c59283e5, topicName=早发)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=06c425715601, createdName=ms7258648636991762, createdTime=Wed Jun 24 08:58:33 CST 2020, time=2020-06-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1639378, encodeId=3d6d16393e8f4, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Mon Sep 07 05:58:33 CST 2020, time=2020-09-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1902396, encodeId=d66d1902396b3, content=<a href='/topic/show?id=c097591ed5' target=_blank style='color:#2F92EE;'>#Diabetes#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5917, encryptionId=c097591ed5, topicName=Diabetes)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=智者为医08, createdTime=Fri Sep 25 20:58:33 CST 2020, time=2020-09-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=380429, encodeId=d4f138042951, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d65b2251967, createdName=12168424m28(暂无昵称), createdTime=Fri Mar 13 23:34:37 CST 2020, time=2020-03-13, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1761335, encodeId=f9331e6133553, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Sat Mar 14 08:58:33 CST 2020, time=2020-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1664097, encodeId=bf77166409e04, content=<a href='/topic/show?id=a20c59283e5' target=_blank style='color:#2F92EE;'>#早发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59283, encryptionId=a20c59283e5, topicName=早发)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=06c425715601, createdName=ms7258648636991762, createdTime=Wed Jun 24 08:58:33 CST 2020, time=2020-06-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1639378, encodeId=3d6d16393e8f4, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Mon Sep 07 05:58:33 CST 2020, time=2020-09-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1902396, encodeId=d66d1902396b3, content=<a href='/topic/show?id=c097591ed5' target=_blank style='color:#2F92EE;'>#Diabetes#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5917, encryptionId=c097591ed5, topicName=Diabetes)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=智者为医08, createdTime=Fri Sep 25 20:58:33 CST 2020, time=2020-09-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=380429, encodeId=d4f138042951, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d65b2251967, createdName=12168424m28(暂无昵称), createdTime=Fri Mar 13 23:34:37 CST 2020, time=2020-03-13, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1761335, encodeId=f9331e6133553, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Sat Mar 14 08:58:33 CST 2020, time=2020-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1664097, encodeId=bf77166409e04, content=<a href='/topic/show?id=a20c59283e5' target=_blank style='color:#2F92EE;'>#早发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59283, encryptionId=a20c59283e5, topicName=早发)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=06c425715601, createdName=ms7258648636991762, createdTime=Wed Jun 24 08:58:33 CST 2020, time=2020-06-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1639378, encodeId=3d6d16393e8f4, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Mon Sep 07 05:58:33 CST 2020, time=2020-09-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1902396, encodeId=d66d1902396b3, content=<a href='/topic/show?id=c097591ed5' target=_blank style='color:#2F92EE;'>#Diabetes#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5917, encryptionId=c097591ed5, topicName=Diabetes)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=智者为医08, createdTime=Fri Sep 25 20:58:33 CST 2020, time=2020-09-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=380429, encodeId=d4f138042951, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d65b2251967, createdName=12168424m28(暂无昵称), createdTime=Fri Mar 13 23:34:37 CST 2020, time=2020-03-13, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1761335, encodeId=f9331e6133553, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Sat Mar 14 08:58:33 CST 2020, time=2020-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1664097, encodeId=bf77166409e04, content=<a href='/topic/show?id=a20c59283e5' target=_blank style='color:#2F92EE;'>#早发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59283, encryptionId=a20c59283e5, topicName=早发)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=06c425715601, createdName=ms7258648636991762, createdTime=Wed Jun 24 08:58:33 CST 2020, time=2020-06-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1639378, encodeId=3d6d16393e8f4, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Mon Sep 07 05:58:33 CST 2020, time=2020-09-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1902396, encodeId=d66d1902396b3, content=<a href='/topic/show?id=c097591ed5' target=_blank style='color:#2F92EE;'>#Diabetes#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5917, encryptionId=c097591ed5, topicName=Diabetes)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=智者为医08, createdTime=Fri Sep 25 20:58:33 CST 2020, time=2020-09-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=380429, encodeId=d4f138042951, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d65b2251967, createdName=12168424m28(暂无昵称), createdTime=Fri Mar 13 23:34:37 CST 2020, time=2020-03-13, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1761335, encodeId=f9331e6133553, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Sat Mar 14 08:58:33 CST 2020, time=2020-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1664097, encodeId=bf77166409e04, content=<a href='/topic/show?id=a20c59283e5' target=_blank style='color:#2F92EE;'>#早发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59283, encryptionId=a20c59283e5, topicName=早发)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=06c425715601, createdName=ms7258648636991762, createdTime=Wed Jun 24 08:58:33 CST 2020, time=2020-06-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1639378, encodeId=3d6d16393e8f4, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Mon Sep 07 05:58:33 CST 2020, time=2020-09-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1902396, encodeId=d66d1902396b3, content=<a href='/topic/show?id=c097591ed5' target=_blank style='color:#2F92EE;'>#Diabetes#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5917, encryptionId=c097591ed5, topicName=Diabetes)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=智者为医08, createdTime=Fri Sep 25 20:58:33 CST 2020, time=2020-09-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=380429, encodeId=d4f138042951, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d65b2251967, createdName=12168424m28(暂无昵称), createdTime=Fri Mar 13 23:34:37 CST 2020, time=2020-03-13, status=1, ipAttribution=)]
    2020-03-13 12168424m28(暂无昵称)

    学习了

    0

相关资讯

2019 共识建议:减重手术后妊娠,围产期、产前和产后护理

本文的主要目的是针对减重手术后妊娠的应该管理和最佳护理提供循证指导。涉及减重手术后女性围产期、产期和产后的护理。

2019 AACE/TOS/ASMBS/OMA/ASA临床实践指南:减重手术围术期营养、代谢以及非手术支持

2019年11月,美国临床内分泌医师学会(AACE)联合多家学会更新发布了减重手术围术期营养、代谢以及非手术支持指南,专家组依据2013年至今的最新证据以及专家建议,对指南中的每项建议进行了评估和更新。主要更新内容涉及以肥胖为基础的慢性疾病并发症中心模型的情景化研究,基于细微差别和算法/检查表辅助的临床决策制定,新的减重手术程序,减重手术术后恢复等。

Hypertension:减重手术可降低顽固性高血压患病率

减重手术是降低血压(BP)的有效策略,但大多数证据依赖于诊室血压测量。Carlos A. Schiavon等研究者开展的这项研究,评估减重手术对24 h血压曲线、血压变异度和顽固性性高血压患病率的影响。

2018 ASMBS指南:儿童代谢和减重手术

2018年7月,美国代谢和减肥外科学会(ASMBS)更新发布了儿童代谢和减重手术指南,该指南的前一版于2012年发布。2018版指南主要基于最新文章对儿童童代谢和减重手术的相关建议进行更新和在评估,指南主要内容涉及肥胖相关疾病、共病以及结局,决策制定,治疗,风险和获益。

Diabetes Obes Metab:减重手术可以使严重肥胖患者升高的GlycA回归正常

由此可见,这是首个证明了手术体重减轻可显著降低GlycA水平的研究。

2019 加拿大共识声明:减重手术后加速康复

加拿大减重外科医生小组共同提出了减重手术后加速康复的共识声明,最终形成14条推荐意见,涉及术前咨询,肠道准备,术前禁食水,术前用药,血栓预防,备皮,麻醉,术中管理和术后营养以及随访等。